Because of the critical involvement of MEK-ERK signaling in a number of chronic diseases and cancer, there has been significant interest in therapeutic approaches to disrupt the docking interaction of MEK and ERK, including the use of small molecule inhibitors [35], the introduction of mutations into the MEK D-site, and transfection of short blocking peptides that bind to the CD domain of ERK [36]. The gene discussed is MAP2K7; the disease is cancer.